Prevention of congenital toxoplasmosis: A critical review of medico-economic studies;Évaluation de stratégies de prévention de la toxoplasmose congénitale: Revue critique des études médico-économiques

Revue d'Epidemiologie et de Sante Publique

Volumn 50, Issue 5, 2002, Pages 475-487

  Binquet, C ^a   Wallon, M ^b   Quantin, C ^a   Gadreau, M ^c   Peyron, F ^b  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b CROIX ROUSSE HOSPITAL   (France)

^c UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Congenital toxoplasmosis; Critical appraisal; Medico economic assessment; Prevention; Screening

Indexed keywords

CALCULATION; CONGENITAL TOXOPLASMOSIS; COST; DECISION MAKING; ECONOMIC ASPECT; HUMAN; METHODOLOGY; PRACTICE GUIDELINE; PRENATAL SCREENING; RELIABILITY; REVIEW; SCORING SYSTEM; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; EVALUATION STUDY; FEMALE; FRANCE; MASS SCREENING; NEWBORN; NEWBORN SCREENING; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; PRENATAL CARE; PRENATAL DIAGNOSIS; PRIMARY PREVENTION; PROCEDURES; STANDARDS; TOXOPLASMOSIS; TOXOPLASMOSIS, CONGENITAL; EVALUATION; PREGNANCY COMPLICATION; STANDARD;

COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; EVALUATION STUDIES AS TOPIC; FEMALE; FRANCE; HUMANS; INFANT, NEWBORN; MASS SCREENING; NEONATAL SCREENING; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; PRENATAL CARE; PRENATAL DIAGNOSIS; PRIMARY PREVENTION; RESEARCH DESIGN; TOXOPLASMOSIS; TOXOPLASMOSIS, CONGENITAL; EVALUATION STUDIES;

EID: 2242466481     PISSN: 03987620     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Peyron F, Wallon M, Bernardoux C. Long-term follow-up of patients with congenital ocular toxoplasmosis. N Engl J Med 1996; 334: 993-4.
2. Derouin F, Nalpas J, Chastang C. Mesure in vitro de l'effet inhibiteur de macrolides lincosamides et synergestines sur la croissance du Toxoplasma gondii. Pathol Biol 1988; 36: 1204-10.
3. Derouin F, Chastang C. Activity in vitro against Toxoplasma gondii of azithromycin and clarythromycin alone and with pyrimethamine. J Antimicrob Chemother 1990; 25: 708-11.
4. Derouin F, Gerard L, Farinotti R, Maslo C, Leport C. Determination of the inhibitory effect of Toxoplasma growth in the serum of AIDS patients during acute therapy for toxoplasmic encephalitis. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19: 50-4.
5. Piketty C, Derouin F, Rouveix B, JJ P. In vivo assessment of antimicrobial agents on Toxoplasma gondii by quantification of parasite in blood, lungs and brain of infected mice. Antimicrob Agents Chemother 1990; 34: 1467-72.
6. Leport C, Raffi F, Matheron S, Katlama C, Regnier B, Saimot A, et al. Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Am J Med 1988; 84: 94-100.
7. Chevallier M. Étude coût-avantage d'un système de prévention de la toxoplasmose congénitale. Statistiques « Santé-Sécurité Sociale » 1974; 3: 71-84.
8. Wallon M, Liou C, Garner P, Peyron F. Congenital toxoplasmosis: Systematic review of evidence of efficacy of treatment in pregnancy. Br Med J 1999; 318: 1511-4.
9. Jeannel D, Costagliola D, Niel G, Hubert B, Danis M. What is known about the prevention of congenital toxoplasmosis? Lancet 1990; 336: 359-61.
10. Holliman RE. Congenital toxoplasmosis: Prevention, screening and treatment. J Hosp Infect 1995; 30: 179-90.
11. Lebech M, Andersen O, Christensen N, Hertel J, Nielsen H, Peitersen B, et al. Feasability of neonatal screening for toxoplasma infection in the absence of prenatal treatment. Lancet 1999; 353: 1834-7.
12. Petersen E, Eaton R. Control of congenital infection with Toxoplasma gondii by neonatal screening based on detection of specific immunoglobulin M antibodies eluted from phenylketonuria filter-paper blood-spot samples. Acta Paediatr Suppl 1999; 88: 36-9.
13. Drummond M, O'Brien B, Stoddard G, Torrance G. Méthode D'évaluation Économique des Programmes de Santé. Paris, Economica, 1997.
14. Collège des Économistes de Santé. Recommandations de bonnes pratiques des méthodes d'évaluation économique des stratégies thérapeutiques. J Econ Med 1998; 16: 329-51.
15. Buzby J, Roberts T. Economic costs and trade impacts of microbial foodborne illness. World Health Stat Q 1997; 50: 57-66.
16. Roberts T, Frenkel JK. Estimating income losses and other preventable costs caused by congenital toxoplasmosis in people in the United States. J Am Vet Med Assoc 1990; 196: 249-56.
17. Roberts T, Murrell K, Marks S. Economic lossses caused by foodborne parasitic diseases. Parasitol Today 1994; 10: 419-23.
18. Roos T, Martius J, Gross U, Schrod L. Systematic serologic screening for toxoplasmosis in pregnancy. Obstet Gynecol 1993; 81: 243-50.
19. Henderson JB, Beattie CP, Hale EG, Wright T. The evaluation of new services: Possibilities for preventing congenital toxoplasmosis. Int J Epidemiol 1984; 13: 65-72.
20. Joss AW, Chatterton JM, Ho-Yen DO. Congenital toxoplasmosis: To screen or not to screen? Public Health 1990; 104: 9-20.
21. Stray-Pedersen B, Jenum P. Economic evaluation of preventive programmes against congenital toxoplasmosis. Scand J Infect Dis 1992; 84: 86-96.
22. Lappalainen M, Sintonen H, Koskiniemi M, Hedman K, Hiilesmaa V, Ammala P, et al. Cost-benefit analysis of screening for toxoplasmosis during pregnancy. Scand J Infect Dis 1995; 27: 265-72.
23. Wilson CB, Remington JS. What can be done to prevent congenital toxoplasmosis? Am J Obstet Gynecol 1980; 138: 357-63.
24. Sagmeister M, Gessner U, Kind C, Horisberger B. Cost-benefit analysis of screening for congenital toxoplasmosis. Schweiz Med Wochenschr 1995; 65: 103S-12S.
25. Mohammed HO, Bowman DD, Anuar AK, Rahmah N. Evaluation of strategies to reduce the risk of congenital toxoplasmosis: A decision tree analysis approach. J Eukaryot Microbiol 1994; 41: 15S.
26. Ancelle T, Goulet V, Tirard-Fleury V, Baril L, du Mazaubrun C. La toxoplasmose chez la femme enceinte en France en 1995. Bull Epidemiol Hebdo 1996; 51: 227-9.
27. Foulon W, Villena I, Stray-Pedersen B, Decoster A, Lappalainen M, Pinon J, et al. Treatment of toxoplasmosis during pregnancy: A multicenter study of impact on fetal transmission and children's sequelae at age 1 year. Am J Obstet Gynecol 1999; 180: 410-5.
28. Baril L, Ancelle T, Goulet V, Thulliez P, Tirard-Fleury V, Carme B. Risk factors for toxoplasma infection in pregnancy: A case-control study in France. Scand J Infect Dis 1999; 31: 305-9.
29. Cook A, Gilbert R, Buffolano W, Zufferey J, Petersen E, Jenum P, et al. Sources of toxoplasma infection in pregnant women: European multicentre case-control study. Br Med J 2000; 321: 142-7.
30. Buxton D, Thomson K, Maley S, Wright S, Bos H. Experimental challenge of sheep 18 months after vaccination with a live (S48) Toxoplasma gondii vaccine. Vet Rec 1993; 133: 310-2.
31. Choromanski L, Freyre A, Popiel R, Brown K, Grieve R, Shibley G. Safety and efficacy of modified feline Toxoplasma gondii vaccine. Dev Biol Stand 1995; 84: 269-81.
32. Frenkel K, Pfefferkorn E, Smith D, Fishback J. Prospective vaccine prepared from a new mutant of Toxoplasma gondii for use in cats. Am J Vet Res 1991; 52: 759-63.
33. Courgenay A. Évaluation du Coût de la Prévention et de la Prise en Charge de la Toxoplasmose Congénitale en France [Thèse de Médecine]. Paris, Université Paris Val-de-Marne, 1997.
34. Dunn D, Wallon M, Peyron F, Petersen E, Peckham C, Gilbert R. Mother-to-child transmission of toxoplasmosis: Risk estimates for clinical counselling. Lancet 1999; 353: 1829-33.